IL6 and plasma cell myeloma: Such findings provided the rationale for clinical trials using targeted inhibitors of IL-6 in patients with cancer (e.g. ovarian cancer, multiple myeloma, renal cell carcinoma, prostate cancer) that showed promising results [24, 36-40].